AB0096 PEP-1-FK506BP12 Inhibits Matrix Metalloproteinase Expression in Human Articular Chondrocytes and in a Mouse Carrageenan-Induced Arthritis Model
BackgroundOsteoarthritis (OA) is a degenerative disease characterized by the death of chondrocytes and the gradual loss of articular cartilage. Recently, transfer of a therapeutic protein into cells by the use of protein transduction domain (PTD) that targets the lipid bilayer directly has been test...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.922-923 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 923 |
---|---|
container_issue | Suppl 2 |
container_start_page | 922 |
container_title | Annals of the rheumatic diseases |
container_volume | 74 |
creator | Park, I.Y. Son, K.M. Kim, H.A. |
description | BackgroundOsteoarthritis (OA) is a degenerative disease characterized by the death of chondrocytes and the gradual loss of articular cartilage. Recently, transfer of a therapeutic protein into cells by the use of protein transduction domain (PTD) that targets the lipid bilayer directly has been tested in terms of therapeutic applications. The FK506-binding protein 12 kDa (FK506BP12) binds immunosuppressive drugs such as FK506 and modulates T cell activation via calcineurin inhibition. The anti-inflammatory properties of and immunomodulatory role played by FK506BP12, independent of FK506, have been demonstrated in several disease modelsObjectivesIn this study, we investigated the ability of PEP-1-FK506BP12, consisting of FK506BP12 fused to the PTD PEP-1 peptide, to suppress catabolic responses in primary human chondrocytes and in a mouse carrageenan-induced paw arthritis model.MethodsWestern blotting and immunofluorescence analysis showed that PEP-1-FK506BP12 efficiently penetrated chondrocytes and cartilage explants.ResultsIn interleukin-1β (IL-1β)-treated chondrocytes, PEP-1-FK506BP12 significantly suppressed the expression of catabolic enzymes, including matrix metalloproteinases (MMPs)-1, -3, and -13; and cyclooxygenase-2, at both the mRNA and protein levels, whereas FK506BP12 alone did not. In addition, PEP-1-FK506BP12 decreased IL-1β-induced phosphorylation of the mitogen-activated protein kinase (MAPK) complex (p38, JNK, and ERK) and the inhibitor kappa B alpha. In the mouse model of carrageenan-induced paw arthritis, PEP-1-FK506BP12 suppressed both carrageenan-induced MMP-13 production and paw inflammation.ConclusionsThus, PEP-1-FK506BP12 may have therapeutic potential in the alleviation of OA progression.ReferencesS.R. Goldring, M.B. Goldring, The role of cytokines in cartilage matrix degeneration in osteoarthritis, Clin. Orthop. Relat. Res. (2004) S27-36.D.W. Kim, S.H. Lee, S.K. Ku, et al., Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model, BMB Rep. 46 (2013) 124-129.S.Y. Kim, E.J. Sohn, D.W. Kim, et al., Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice, J. Invest. Dermatol. 131 (2013) 1477-1485.AcknowledgementsThis research was supported by a grant (A120960) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, by National Research Foundation of Korea; Mid-career Research program grant (NRF-2009-0084569), and by Hallym University Rese |
doi_str_mv | 10.1136/annrheumdis-2015-eular.2021 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901779105</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322502429</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1275-c0d0682baa3c422b0852eb33706157b5d5542737ef303e0ed780c184135fc1553</originalsourceid><addsrcrecordid>eNqVkc1uEzEURi0EEqHtO1jq2uVee2xPxCqNUhrRqFnQteUZO8TRxA72jNTuuuEdeD6ehBnCgi0r61rfuT86hFwj3CAK9dHGmPd-OLpQGAeUzA-dzTccOL4hM6xUPX4reEtmACBYNVf6PflQymEsocZ6Rn4ubgHm6tfrj-1qy5DdfZGgbrfI6TruQxP6Qje2z-GZbnxvuy6dcup9iLZ4uno-ZV9KSJGGSO-Ho410kfvQTkvQ5T5Fl1P70vtCbXRTxtJNGkZyaXO237yPNrJ1dEPr3UTuc-jDODA5312SdzvbFX_1970gT3err8t79vD4eb1cPLAGuZasBQeq5o21oq04b6CW3DdCaFAodSOdlBXXQvudAOHBO11Di3WFQu5alFJckOtz3_Gw74MvvTmkIcdxpME5oNZzhCn16Zxqcyol-5055XC0-cUgmEmF-UeFmVSYPyrMpGKk1Zlujof_An8DaK2UyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901779105</pqid></control><display><type>article</type><title>AB0096 PEP-1-FK506BP12 Inhibits Matrix Metalloproteinase Expression in Human Articular Chondrocytes and in a Mouse Carrageenan-Induced Arthritis Model</title><source>BMJ Journals Online</source><creator>Park, I.Y. ; Son, K.M. ; Kim, H.A.</creator><creatorcontrib>Park, I.Y. ; Son, K.M. ; Kim, H.A.</creatorcontrib><description>BackgroundOsteoarthritis (OA) is a degenerative disease characterized by the death of chondrocytes and the gradual loss of articular cartilage. Recently, transfer of a therapeutic protein into cells by the use of protein transduction domain (PTD) that targets the lipid bilayer directly has been tested in terms of therapeutic applications. The FK506-binding protein 12 kDa (FK506BP12) binds immunosuppressive drugs such as FK506 and modulates T cell activation via calcineurin inhibition. The anti-inflammatory properties of and immunomodulatory role played by FK506BP12, independent of FK506, have been demonstrated in several disease modelsObjectivesIn this study, we investigated the ability of PEP-1-FK506BP12, consisting of FK506BP12 fused to the PTD PEP-1 peptide, to suppress catabolic responses in primary human chondrocytes and in a mouse carrageenan-induced paw arthritis model.MethodsWestern blotting and immunofluorescence analysis showed that PEP-1-FK506BP12 efficiently penetrated chondrocytes and cartilage explants.ResultsIn interleukin-1β (IL-1β)-treated chondrocytes, PEP-1-FK506BP12 significantly suppressed the expression of catabolic enzymes, including matrix metalloproteinases (MMPs)-1, -3, and -13; and cyclooxygenase-2, at both the mRNA and protein levels, whereas FK506BP12 alone did not. In addition, PEP-1-FK506BP12 decreased IL-1β-induced phosphorylation of the mitogen-activated protein kinase (MAPK) complex (p38, JNK, and ERK) and the inhibitor kappa B alpha. In the mouse model of carrageenan-induced paw arthritis, PEP-1-FK506BP12 suppressed both carrageenan-induced MMP-13 production and paw inflammation.ConclusionsThus, PEP-1-FK506BP12 may have therapeutic potential in the alleviation of OA progression.ReferencesS.R. Goldring, M.B. Goldring, The role of cytokines in cartilage matrix degeneration in osteoarthritis, Clin. Orthop. Relat. Res. (2004) S27-36.D.W. Kim, S.H. Lee, S.K. Ku, et al., Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model, BMB Rep. 46 (2013) 124-129.S.Y. Kim, E.J. Sohn, D.W. Kim, et al., Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice, J. Invest. Dermatol. 131 (2013) 1477-1485.AcknowledgementsThis research was supported by a grant (A120960) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, by National Research Foundation of Korea; Mid-career Research program grant (NRF-2009-0084569), and by Hallym University Research Fund.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.2021</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.922-923</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/922.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/922.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,777,781,3183,23552,27905,27906,77349,77380</link.rule.ids></links><search><creatorcontrib>Park, I.Y.</creatorcontrib><creatorcontrib>Son, K.M.</creatorcontrib><creatorcontrib>Kim, H.A.</creatorcontrib><title>AB0096 PEP-1-FK506BP12 Inhibits Matrix Metalloproteinase Expression in Human Articular Chondrocytes and in a Mouse Carrageenan-Induced Arthritis Model</title><title>Annals of the rheumatic diseases</title><description>BackgroundOsteoarthritis (OA) is a degenerative disease characterized by the death of chondrocytes and the gradual loss of articular cartilage. Recently, transfer of a therapeutic protein into cells by the use of protein transduction domain (PTD) that targets the lipid bilayer directly has been tested in terms of therapeutic applications. The FK506-binding protein 12 kDa (FK506BP12) binds immunosuppressive drugs such as FK506 and modulates T cell activation via calcineurin inhibition. The anti-inflammatory properties of and immunomodulatory role played by FK506BP12, independent of FK506, have been demonstrated in several disease modelsObjectivesIn this study, we investigated the ability of PEP-1-FK506BP12, consisting of FK506BP12 fused to the PTD PEP-1 peptide, to suppress catabolic responses in primary human chondrocytes and in a mouse carrageenan-induced paw arthritis model.MethodsWestern blotting and immunofluorescence analysis showed that PEP-1-FK506BP12 efficiently penetrated chondrocytes and cartilage explants.ResultsIn interleukin-1β (IL-1β)-treated chondrocytes, PEP-1-FK506BP12 significantly suppressed the expression of catabolic enzymes, including matrix metalloproteinases (MMPs)-1, -3, and -13; and cyclooxygenase-2, at both the mRNA and protein levels, whereas FK506BP12 alone did not. In addition, PEP-1-FK506BP12 decreased IL-1β-induced phosphorylation of the mitogen-activated protein kinase (MAPK) complex (p38, JNK, and ERK) and the inhibitor kappa B alpha. In the mouse model of carrageenan-induced paw arthritis, PEP-1-FK506BP12 suppressed both carrageenan-induced MMP-13 production and paw inflammation.ConclusionsThus, PEP-1-FK506BP12 may have therapeutic potential in the alleviation of OA progression.ReferencesS.R. Goldring, M.B. Goldring, The role of cytokines in cartilage matrix degeneration in osteoarthritis, Clin. Orthop. Relat. Res. (2004) S27-36.D.W. Kim, S.H. Lee, S.K. Ku, et al., Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model, BMB Rep. 46 (2013) 124-129.S.Y. Kim, E.J. Sohn, D.W. Kim, et al., Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice, J. Invest. Dermatol. 131 (2013) 1477-1485.AcknowledgementsThis research was supported by a grant (A120960) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, by National Research Foundation of Korea; Mid-career Research program grant (NRF-2009-0084569), and by Hallym University Research Fund.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkc1uEzEURi0EEqHtO1jq2uVee2xPxCqNUhrRqFnQteUZO8TRxA72jNTuuuEdeD6ehBnCgi0r61rfuT86hFwj3CAK9dHGmPd-OLpQGAeUzA-dzTccOL4hM6xUPX4reEtmACBYNVf6PflQymEsocZ6Rn4ubgHm6tfrj-1qy5DdfZGgbrfI6TruQxP6Qje2z-GZbnxvuy6dcup9iLZ4uno-ZV9KSJGGSO-Ho410kfvQTkvQ5T5Fl1P70vtCbXRTxtJNGkZyaXO237yPNrJ1dEPr3UTuc-jDODA5312SdzvbFX_1970gT3err8t79vD4eb1cPLAGuZasBQeq5o21oq04b6CW3DdCaFAodSOdlBXXQvudAOHBO11Di3WFQu5alFJckOtz3_Gw74MvvTmkIcdxpME5oNZzhCn16Zxqcyol-5055XC0-cUgmEmF-UeFmVSYPyrMpGKk1Zlujof_An8DaK2UyA</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Park, I.Y.</creator><creator>Son, K.M.</creator><creator>Kim, H.A.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>AB0096 PEP-1-FK506BP12 Inhibits Matrix Metalloproteinase Expression in Human Articular Chondrocytes and in a Mouse Carrageenan-Induced Arthritis Model</title><author>Park, I.Y. ; Son, K.M. ; Kim, H.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1275-c0d0682baa3c422b0852eb33706157b5d5542737ef303e0ed780c184135fc1553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, I.Y.</creatorcontrib><creatorcontrib>Son, K.M.</creatorcontrib><creatorcontrib>Kim, H.A.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, I.Y.</au><au>Son, K.M.</au><au>Kim, H.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0096 PEP-1-FK506BP12 Inhibits Matrix Metalloproteinase Expression in Human Articular Chondrocytes and in a Mouse Carrageenan-Induced Arthritis Model</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>922</spage><epage>923</epage><pages>922-923</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundOsteoarthritis (OA) is a degenerative disease characterized by the death of chondrocytes and the gradual loss of articular cartilage. Recently, transfer of a therapeutic protein into cells by the use of protein transduction domain (PTD) that targets the lipid bilayer directly has been tested in terms of therapeutic applications. The FK506-binding protein 12 kDa (FK506BP12) binds immunosuppressive drugs such as FK506 and modulates T cell activation via calcineurin inhibition. The anti-inflammatory properties of and immunomodulatory role played by FK506BP12, independent of FK506, have been demonstrated in several disease modelsObjectivesIn this study, we investigated the ability of PEP-1-FK506BP12, consisting of FK506BP12 fused to the PTD PEP-1 peptide, to suppress catabolic responses in primary human chondrocytes and in a mouse carrageenan-induced paw arthritis model.MethodsWestern blotting and immunofluorescence analysis showed that PEP-1-FK506BP12 efficiently penetrated chondrocytes and cartilage explants.ResultsIn interleukin-1β (IL-1β)-treated chondrocytes, PEP-1-FK506BP12 significantly suppressed the expression of catabolic enzymes, including matrix metalloproteinases (MMPs)-1, -3, and -13; and cyclooxygenase-2, at both the mRNA and protein levels, whereas FK506BP12 alone did not. In addition, PEP-1-FK506BP12 decreased IL-1β-induced phosphorylation of the mitogen-activated protein kinase (MAPK) complex (p38, JNK, and ERK) and the inhibitor kappa B alpha. In the mouse model of carrageenan-induced paw arthritis, PEP-1-FK506BP12 suppressed both carrageenan-induced MMP-13 production and paw inflammation.ConclusionsThus, PEP-1-FK506BP12 may have therapeutic potential in the alleviation of OA progression.ReferencesS.R. Goldring, M.B. Goldring, The role of cytokines in cartilage matrix degeneration in osteoarthritis, Clin. Orthop. Relat. Res. (2004) S27-36.D.W. Kim, S.H. Lee, S.K. Ku, et al., Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model, BMB Rep. 46 (2013) 124-129.S.Y. Kim, E.J. Sohn, D.W. Kim, et al., Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice, J. Invest. Dermatol. 131 (2013) 1477-1485.AcknowledgementsThis research was supported by a grant (A120960) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, by National Research Foundation of Korea; Mid-career Research program grant (NRF-2009-0084569), and by Hallym University Research Fund.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.2021</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.922-923 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1901779105 |
source | BMJ Journals Online |
title | AB0096 PEP-1-FK506BP12 Inhibits Matrix Metalloproteinase Expression in Human Articular Chondrocytes and in a Mouse Carrageenan-Induced Arthritis Model |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T16%3A02%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0096%E2%80%85PEP-1-FK506BP12%20Inhibits%20Matrix%20Metalloproteinase%20Expression%20in%20Human%20Articular%20Chondrocytes%20and%20in%20a%20Mouse%20Carrageenan-Induced%20Arthritis%20Model&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Park,%20I.Y.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=922&rft.epage=923&rft.pages=922-923&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.2021&rft_dat=%3Cproquest_cross%3E4322502429%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901779105&rft_id=info:pmid/&rfr_iscdi=true |